Back to News
Market Impact: 0.45

Kimberly-Clark (KMB) Nears $3.5B Sale of Tissue Business to Suzano

KMBSUZ
M&A & RestructuringAnalyst EstimatesAnalyst InsightsCompany FundamentalsCorporate Guidance & Outlook
Kimberly-Clark (KMB) Nears $3.5B Sale of Tissue Business to Suzano

Kimberly-Clark is set to divest its non-North American Kleenex and tissue business to Suzano for $3.5 billion, enabling a strategic refocus on core segments. Wall Street analysts project a slight upside with an average price target of $144.13, while GuruFocus's GF Value suggests a potential 4.69% downside, reflecting mixed market sentiment as the company undergoes restructuring.

Analysis

Kimberly-Clark (NYSE: KMB) is strategically repositioning by divesting its non-North American Kleenex and tissue operations to Brazilian company Suzano for approximately $3.5 billion, a move designed to enable KMB to concentrate on its more profitable core segments. This significant corporate action is met with a mixed valuation outlook from financial analysts; forecasts from 17 analysts suggest an average price target of $144.13 for KMB, implying a 4.12% potential upside from its current price of $138.43, with projections ranging from $118.00 to $162.00. Conversely, GuruFocus's GF Value projects a value of $131.94, indicating a potential downside of 4.69%. This divergence aligns with the consensus "Hold" recommendation from 20 brokerage firms, which assign KMB an average rating of 2.8 (on a 1-Strong Buy to 5-Sell scale), reflecting a cautious market sentiment amid the ongoing restructuring and a general sentiment score of 0.1, labeled as mixed.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment